Format

Send to

Choose Destination
J Neurotrauma. 1999 Dec;16(12):1131-8.

Evaluation of designs for clinical trials of neuroprotective agents in head injury. European Brain Injury Consortium.

Author information

1
Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA.

Abstract

In a study involving the statistical modeling of potential head injury trials, we explore approaches to trial design that could enhance their power to detect treatment-related effects on clinical outcome. The study uses a survey organized by the European Brain Injury Consortium of over 1,000 head-injured patients to characterize the population from which trial participants can be selected. A variety of models are postulated for the effects of "neuroprotective" treatment on outcome, and their interaction with a range of strategies for targeting patients for inclusion in the trial is evaluated. A very simple strategy of targeting patients with an intermediate prognosis was found to allow a reduction in sample size by 30%, with no reduction in statistical power. This paper illustrates an important methodology for studying the characteristics of competing trial designs.

PMID:
10619192
DOI:
10.1089/neu.1999.16.1131
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center